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INTRODUCTION
Mutations in a variety of genes underlie different skin 
pathologies, in either monogenic or multigenic diseases. In 
vivo model systems are essential to investigate the contri-
bution of the different proteins encoded by these genes to 
disease development. Furthermore, these models are neces-
sary to develop and test new treatments for these diseases. 
Gene-targeting strategies in mice allow investigators to turn 
genes off or on, either in the whole organism or in a tissue-
specific manner (Gu et al., 1994). Strategies to inactivate 
genes using Cre–loxP technology, for example, were intro-
duced in the first part of the “Transgenic Mouse Technology 
in Skin Biology” Research Techniques Made Simple article 
(Scharfenberger et al., 2014). However, many complete 
and tissue-specific Cre-mediated knockout mice result in 
embryonic or early perinatal death, thereby precluding 
the analysis of gene function in different cell types and in 
the regulation of skin homeostasis (Lewandoski, 2001). In 
addition, many skin diseases only manifest in adult stages 
of life, and this is often accompanied by an altered gene 
expression. To circumvent early lethality and/or mimic the 
alterations in gene expression that precede or accompany 
disease, several transgenic mouse systems have been devel-
oped, which allow investigators not only to regulate gene 
expression in a tissue/cell-specific manner (spatial control) 
but also to initiate this alteration at a time point that is deter-
mined by the researcher (temporal control).
Several inducible systems have recently been developed, 
each with different advantages and limitations (Garcia and 
Mills, 2002; Lewandowski, 2001). Some of these inducible 
systems are based on spatiotemporal control of promoter 
activity by regulatory elements inserted in front of the pro-
moter, whereas in other systems the spatial localization of the 
protein of interest (mostly Cre) determines whether the pro-
tein is active. Using Cre as an example of a spatiotemporally 
induced protein, we will discuss the two most common 
models: the tetracycline/doxycycline binary transactivation 
model and the tamoxifen–Cre–inducible model.
THE TETRACYCLINE-INDUCIBLE CRE–LOXP SYSTEM
Tetracycline (Tet)-inducible systems use an artificial protein (tet-
racycline-responsive transactivator (tTA)) to regulate the expres-
sion of proteins of interest (Garcia and Mills, 2002; Figure 1). As 
an example we use the Cre protein, which can control the tim-
ing of Cre-mediated recombination of loxP sites. The tTA fusion 
protein is composed of the tetracycline repressor from bacteria 
and the viral protein p16 (used by Jaubert et al., 2004). tTA is 
able to bind to a 19 base pair–long DNA sequence (tet Operon 
(tetO)) and induce the expression of the gene of interest that 
is inserted after the tetO (in this case the Cre recombinase). In 
the presence of the antibiotic Tet or its derivative, doxycycline 
ADVANTAGES 
•  Inducible mouse technology enables investigators 
to determine not only where but also when to turn 
on or off genes of interest.
•  It also allows investigators to assess the functional 
importance of overexpression or loss of proteins 
in normal skin homeostasis and at different stages 
of disease.
LIMITATIONS 
•  Long-term treatment with the inducer can lead to 
side effects.
•  The system can be “leaky,” resulting in undesired 
expression of the protein of interest.
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(Dox), tTA changes its confirmation and the tTA is no longer able 
to bind to the tetO, thus shutting down expression of the Cre 
recombinase (Garcia and Mills, 2002). Inactivation of a gene at 
the time point of interest requires the persistent application of 
Tet/Dox until this time point (Jaubert et al., 2004). Upon clear-
ance of Tet/Dox from the tissue, the Cre recombinase is active, 
resulting in recombination of the loxP sites and, in the case of 
deletion, inactivation of the gene (Figure 1a).
The main disadvantage of this so-called Tet-off system is the 
high toxicity of Tet/Dox when used in the long-term treatment 
of mice. To circumvent this problem the “Tet-on” system was 
developed, where a reverse tTa (rtTA) protein (Jaubert et al., 
2004) only binds to the DNA upon binding to Tet/Dox, which 
then results in activation of Cre expression (Figure 1b). The 
advantage of this method is that mice do not have to be treated 
continuously with Tet/Dox. In addition, expression of the Cre 
recombinase solely depends on saturation of the drug in the tis-
sue. Using cell/tissue-specific promoters to drive tTA/rtTA fusion 
protein expression allows spatial control of the turning off or on 
of genes in the tissue or cells of interest.
THE TAMOXIFEN-INDUCIBLE CRE–LOXP SYSTEM
The second major inducible gene knockout/knockin system is 
based on nuclear hormone receptors that translocate into the 
nucleus to regulate gene expression when bound to their corre-
sponding hormone ligand (Garcia and Mills, 2002; Lewandoski, 
2001; Figure 2). The estrogen receptor (ER) is such a nuclear 
hormone receptor that binds estrogen, but also the estrogen 
antagonist tamoxifen. In the inactive state the ER is bound to 
heat shock protein 90 (Hsp90) and is thereby excluded from 
the nucleus. When estrogen or tamoxifen binds the hormone-
binding site of the ER, Hsp90 is released and the ER shuttles into 
the nucleus. This property is used to control the localization of 
Cre, which can only recombine loxP sites in the nucleus. By 
fusing Cre to the ER, it is retained in the cytosol by Hsp90 in 
the absence of hormone. Upon application of tamoxifen, the 
Cre–ER protein is released from Hsp90 and can now enter the 
nucleus, where Cre recombines the loxP-flanked (floxed) target 
gene. This system uses modified versions of the estrogen recep-
tors, which cannot bind endogenous estrogen but are able to 
bind tamoxifen. The expression of this Cre–ER fusion protein is 
controlled by tissue-specific promoters (Gu et al., 1994; Denton 
et al., 2009; Figure 3).
APPLICATION METHODS
Tet/Dox and tamoxifen dissolved in a vehicle, such as ethanol, 
can be applied topically to a defined area of mammal skin. 
When a systemic approach is favored, tTA or rtTA mice are 
usually fed Dox-containing drinking water to induce gene dele-
tion. For tamoxifen-inducible Cre–ER systems, the application 
methods are more diverse. Similar to Dox treatment, the mice 
can be fed tamoxifen drinking water or tamoxifen food pellets. 
This is a convenient method for investigators, and it is consider-
ably less stressful for the mice compared to other procedures. 
When using these food- and water-based application methods, 
the gene deletion efficiency depends on the animals’ drinking 
and eating behavior, which directly correlates to the final Dox 
or tamoxifen dosage in the target tissue.
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Figure 1. Tetracycline/doxycycline-inducible Cre–loxP system. (a) The Tet/
Dox-responsive tetracycline-responsive transactivator (tTA) protein, which 
is expressed under the control of a tissue-specific promoter, can bind Tet/
Dox. Upon Tet/Dox application, the tTA is unable to bind the tet Operon 
(tetO), resulting in an inactive promoter and no expression of the protein of 
interest, in this case Cre recombinase. When Tet/Dox is removed, tTA is able 
to bind the tetO element, resulting in activation of the promoter and, thus, 
expression of Cre (Tet-off). (b) The Tet-on system uses a modified reverse tTA 
(rtTA) protein, which can be activated by Tet/Dox. Upon Tet/Dox application, 
the rtTA protein is able to bind the tetO and activate the promoter, resulting 
in expression of the protein of Cre. Subsequently, Cre can then recombine 
the floxed gene of interest, thus leading to gene inactivation.
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In addition, the relatively low water solubility of tamoxi-
fen limits the tamoxifen doses that can be administered 
via drinking water, making it more difficult to arrive at a 
dose sufficient for gene knockout. These feeding or drink-
ing variations can be circumvented by the use of a feed-
ing needle, which, however, increases stress for the mice. 
Intraperitoneal or subcutaneous injections are also common 
using tamoxifen resolved in corn oil (Figure 3b). The subcu-
taneous implantation of tamoxifen pellets can also be used 
in rodents. Often, finding the right method to achieve the 
best possible deletion efficiency using these systems can be 
challenging and requires considerable testing.
ADVANTAGES AND LIMITATIONS
The main advantage of inducible gene expression models 
is the temporal control of gene expression or deletion by 
the external application of a drug. It is an elegant method 
to overcome problems such as prenatal lethality caused by 
conventional or tissue-specific inactivation of genes, and it 
enables the control of gene expression at specific time points. 
This is especially appealing for studying specific gene func-
tion at specific time points during development and homeo-
stasis and, importantly, allows investigators to turn genes on 
or off at different disease stages, enabling assessment of their 
importance during the progression of various diseases.
Inducible systems also have several limitations. Beside 
the problem of choosing the right drug application methods 
to achieve induction of expression and/or deletion, there 
are other pitfalls when using these systems. One problem is 
determining the dose of Dox or tamoxifen. If the dose is too 
high or the time of treatment is too long, toxic side effects can 
occur and ruin an experiment. Doses that are too low may 
result in insufficient induction of the protein of interest (e.g., 
Cre), resulting in only a partial gene knockout. Furthermore, 
tamoxifen can interfere with the endogenous ER pathway 
and might therefore have additional unwanted effects.
As in conditional knockout approaches, the locus of the 
target gene is important for recombinase efficiency and varies 
among tissues. In addition, the recombination efficiency of 
fusion proteins, such as Cre–ER, can vary in different areas of 
the tissue, resulting in genetic mosaicism (Schwenk et al., 1998; 
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Figure 2. Tamoxifen-inducible Cre–loxP system. The protein of interest 
(here the Cre recombinase) is fused to a modified estrogen receptor (ER) 
and controlled by a tissue-specific promoter. In the unactivated state, heat 
shock protein 90 (Hsp90) binds to the ER, retaining it in the cytosol. Upon 
tamoxifen treatment, tamoxifen binds the ER, the Hsp90 protein is released, 
and the Cre–ER fusion protein can translocate in the nucleus. In the nucleus, 
the Cre recombines the floxed gene, resulting in a knockout.
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Figure 3. Inducible fibroblast-specific deletion of TbII. The Cre–estrogen 
receptor (ER) is expressed under the control of the fibroblast-specific Col1a2 
promoter. The Col1a2-Cre-ERT mice were crossed with the TbRII floxed mice. 
Treatment with tamoxifen leads to a fibroblast-specific deletion of exon 4 
of the TbRII protein. (b) The successful deletion of exon 4 by intraperitoneal 
injection of tamoxifen was confirmed by PCR. The 692-bp PCR product from 
the null allele (P3, P5) is present only after tamoxifen administration. (c, d) 
Lysates from fibroblasts cultured from skin biopsies (c) and immunostainings 
on explanted skin fibroblasts (d) confirm the absence of TbRII after tamoxifen 
treatment. (Adapted from Denton et al., 2009.)
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Lewandoski, 2001). A prominent problem in many inducible 
knockout methods is the “leakiness” of the system, meaning 
that the Cre recombinase has an unwanted weak activity inde-
pendent of the inducing substance. For example, in the tTA sys-
tem a reduction of Dox levels in the tissue can lead to undesired 
gene deletion in some cells, leading to an effect before the actu-
al experiment even starts. Similar problems have been observed 
for the Cre–ER mouse models (Garcia and Mills, 2002).
Despite these disadvantages and the sometimes labor-inten-
sive testing of these mouse models, they offer a great oppor-
tunity for spatiotemporal control of gene expression and the 
assessment of gene function in vivo—not only during normal 
skin homeostasis but also at various stages of skin disease.
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1.  What is a possible disadvantage of total-body 
knockout mice?
A. The researcher induces the knockout.
B. The knockout is tissue specific.
C. The knockout is embryonic lethal.
2.  Which of the following statements is incorrect?
A.  The tetracycline-responsive transactivator (tTA 
or rtTA) binds to the promoter of the target gene 
(knockout).
B.  The tetracycline-responsive transactivator  
(tTA or rtTA) binds to the tet Operon (tetO).
C.  The tetracycline-responsive transactivator  
(tTA or rtTA) is modulated by Dox.
3.  Which protein in the cytoplasm binds the  
estrogen-fusion protein?
A.  Hsp70.
B.  Hsp90.
C. BAG-3.
D. NEMO.
4.  Which method is not preferred for tamoxifen 
treatment?
A. Feeding with tamoxifen food pellets.
B.  Subcutaneous injections.
C.  Adding tamoxifen to the drinking water.
D. Applying tamoxifen to the skin.
5.  What needs to be checked after treatment of the 
mice before further investigation?
A. Check for deletion efficiency of the target gene.
B.  Check for alterations of related signaling path-
ways.
C.  Check the skin of these mice for a phenotype.
D. Check for behavioral changes of the mice.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
